First and only PARP inhibitor to improve invasive disease-free survival in patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Acceptance based on results from the phase 3 KEYNOTE-091 trial
No new studies have been requested
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
